Brief: Aeterna Zentaris Provides Update On Macrilen® (Macimorelin), Reiterates Advancement Of Pediatric Detect Trial

COSCIENS Biopharma

05/04/2023 13:52

April 5 (Reuters) - Aeterna Zentaris Inc:
    * AETERNA ZENTARIS PROVIDES UPDATE ON MACRILEN®
(MACIMORELIN),
REITERATES ADVANCEMENT OF PEDIATRIC DETECT TRIAL
    * AETERNA ZENTARIS INC - U.S. SALES OF MACRILEN(®) FOR ADULT
USE
TO BE TEMPORARILY DISCONTINUED AS OF MAY 23, 2023
    * AETERNA ZENTARIS INC - DETECT TRIAL CONTINUES IN ORDER TO
EXPAND
OPPORTUNITY FOR PEDIATRIC USAGE OF MACRILEN
    * AETERNA ZENTARIS INC - DETECT TRIAL CONTINUES IN ORDER TO
EXPAND
OPPORTUNITY FOR PEDIATRIC USAGE OF MACRILEN
    * AETERNA ZENTARIS: SEEKS ALTERNATE DEVELOPMENT,
COMMERCIALIZATION
PARTNERS FOR MACRILEN IN US AND OTHER TERRITORIES CURRENTLY NOT
PARTNERED
    * AETERNA ZENTARIS INC - USPTO ISSUES NOTICE OF ALLOWANCE
FOR
AETERNA U.S. PATENT APPLICATION FOR MACIMORELIN
    * AETERNA ZENTARIS - SALES & COMMERCIALIZATION EFFORTS
CONTINUE TO
MOVE FORWARD IN EUROPEAN ECONOMIC AREA AND UK UNDER RECENT
AGREEMENT WITH PHARMANOVIA

Further company coverage:  AEZS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))